[144] Cadrenal Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 notifying the proposed sale of 1,500 common shares through Morgan Stanley Smith Barney on 09/24/2025 with an aggregate market value of $20,520 and 2,046,854 shares outstanding. The shares were acquired as Founders Shares on 05/17/2022. The filing also discloses recent 10b5-1 sales by the same account on 08/27/2025 (1,600 shares, $22,392) and 08/28/2025 (400 shares, $5,600). The filer certifies no undisclosed material adverse information and indicates reliance on established trading procedures where applicable.

Positive

• Rule-compliant disclosure of proposed sale under Form 144 with broker identified
• Prior 10b5-1 sales disclosed, indicating use of prearranged trading plans

Negative

• Insider selling of founder shares may be viewed negatively by some investors
• Form lacks contextual details about remaining insider holdings or any transfer restrictions

Insights

Securities Compliance Analyst

TL;DR: Founder-originated shares being sold under Rule 144 and prior 10b5-1 trades are disclosed; procedural compliance appears intact.

The Form 144 details a modest disposition of 1,500 common shares by a holder of founders shares, acquired on 05/17/2022, scheduled for sale on 09/24/2025 via Morgan Stanley Smith Barney. The filing also lists two recent 10b5-1 plan sales totaling 2,000 shares in August 2025, with combined gross proceeds of $28, - (note: proceeds shown as $28, - in source must be read as $28, - per itemized rows). The signer affirms no material non-public information and references Rule 10b5-1 compliance, which is relevant for insider trading defenses. Documentation is standard for a Rule 144 notice and does not, by itself, indicate regulatory issues.

Corporate Governance Specialist

TL;DR: Insider share sales are documented; amounts are small relative to many public-company float disclosures but require monitoring.

The filing shows a founder-originated position being partially liquidated. The combination of a Form 144 notice and prior 10b5-1 sales signals planned, rule-compliant disposals rather than ad hoc market exits. For governance review, important details—such as whether lock-up or other transfer restrictions apply—are not included in this form. The disclosure meets Rule 144 procedural requirements but does not provide context on remaining insider holdings or dilution effects.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1500	20520.00	2046854	09/24/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/17/2022	Founders Shares	Issuer			1500	05/17/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	08/28/2025	400	5600.00
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	08/27/2025	1600	22392.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Cadrenal Therapeutics' (CVKD) Form 144 notify?

The filing notifies a proposed sale of 1,500 common shares valued at $20,520 to be executed on 09/24/2025 via Morgan Stanley Smith Barney.

When were the shares being sold originally acquired?

The shares were acquired as Founders Shares on 05/17/2022, according to the Form 144.

Does the filing show any recent related sales by the same person?

Yes. The filing lists two 10b5-1 plan sales in August 2025: 1,600 shares on 08/27/2025 for $22,392 and 400 shares on 08/28/2025 for $5,600.

Which broker is handling the proposed sale?

The proposed sale is to be handled by Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.

Does the filer assert possession of material non-public information?

The signer represents that they do not know any material adverse information about the issuer that has not been publicly disclosed.